Resolution:
## Figure 2.
Sensitivity analysis. The sensitivity analysis estimated the minimum difference in panitumumab concentration
between antibody-positive and antibody-negative samples that could be statistically
significant (P < 0.05) with respect to the model prediction. Results show that the current observed
sample size for pharmacokinetic testing (n = 38) from antibody-positive patients was
only adequate to detect a difference of > 55%. Approximately 200 and 650 samples from
antibody-positive patients would be required to detect differences of 38% and 20%,
respectively.
Weeraratne |